[Clinical problems in the treatment of myeloid leukemia in childhood].
As for childhood AML, intensification of chemotherapy and advance in supportive care have contributed toward the patient survival. In addition to prevent early death, we have to develop a risk classification and appropriate therapies with updated genomics, especially for the intermediate risk group which has much diversity. Also, new treatment strategies utilizing various molecular-targeted therapies are required. For childhood CML, the possibilities of unknown risks which accompanied by life-long imatinib treatment should be considered. Comparing SCT and imatinib, We need to make an original treatment guideline for child CML. Furthermore, according to the increase of long-term survivors, the late adverse effects showed up. We should aim for "full recovery" and hope to have a long-term follow up and feedback system for the survivors.
Kiyotani
Chikako
C
Department of Hematology/Oncology, National Center for Child Health and Development.
Kiyokawa
Nobutaka
N
Mori
Tetsuya
T
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001549:Benzamides; D002648:Child; D003141:Communicable Diseases / Q000209:etiology; D004314:Down Syndrome; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D000068877:Imatinib Mesylate; D007951:Leukemia, Myeloid / Q000145:classification / Q000235:genetics / Q000628:therapy*; D008297:Male; D010879:Piperazines / Q000008:administration & dosage; D017410:Practice Guidelines as Topic; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage; D011743:Pyrimidines / Q000008:administration & dosage; D012074:Remission Induction; D012306:Risk
D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate